Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 1;107(10):2523-2526.
doi: 10.3324/haematol.2022.281398.

Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia

Naseema Gangat  1 , Jonathan Bleeker  2 , Douglas Lynch  2 , Horatiu Olteanu  3 , Louis Letendre  4 , Ayalew Tefferi  4
Affiliations

Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia

Naseema Gangat et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Bone marrow biopsy findings pre- and post-treatment with daratumumab. (A) Bone marrow biopsy pre-treatment with daratumumab. Bone marrow (BM) aspirate (500x magnification), core biopsy (100x magnification) and immunohistochemical stains (100x magnification) performed on the core biopsy. The findings show decreased erythropoiesis with left shift as demonstrated by scattered E-cadherin-positive pronormoblasts and very rare hemoglobin-positive maturing erythroids, a normal number of myelomonocytic elements (positive for myeloperoxidase) and 5-9% CD138-positive plasma cells. (B) BM biopsy post-treatment with daratumumab. BM aspirate (500x magnification), core biopsy (100x magnification) and clot section (100x magnification). The findings show a normocellular BM for age, with morphologically unremarkable trilineage hematopoiesis, including an adequate number of erythroid precursors. CD138 immunohistochemical stain demonstrates increased plasma cells (up to 10%). κ and λ light chain in situ hybridization demonstrates κ light chain restriction within the plasma cells.
Figure 2.
Figure 2.
Pre- and post-daratumumab changes in hemoglobin levels, reticulocyte percentage and monoclonal protein studies.
See this image and copyright information in PMC

References

    1. Gurnari C, Maciejewski JP. How I manage acquired pure red cell aplasia in adults. Blood. 2021;137(15):2001-2009. - PMC - PubMed
    1. Balasubramanian SK, Sadaps M, Thota S, et al. . Rational management approach to pure red cell aplasia. Haematologica. 2018;103(2):221-230. - PMC - PubMed
    1. Korde N, Zhang Y, Loeliger K, et al. . Monoclonal gammopathy-associated pure red cell aplasia. Br J Haematol. 2016;173(6):876-883. - PMC - PubMed
    1. Martino R, García-Cadenas I, Esquirol A. Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation. Bone Marrow Transplant. 2022;57(2):282-285. - PMC - PubMed
    1. Chapuy CI, Kaufman RM, Alyea EP, Connors JM. Daratumumab for delayed red-cell engraftment after allogeneic transplantation. N Engl J Med. 2018;379(19):1846-1850. - PubMed

MeSH terms